Clinical trial · Observational
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia
PHF19 Gene Expression and EZH2 Gene Deletion as Potential Biomarkers of Acute Myeloid Leukemia
NCT04215822CI-TRIAL-00042581unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study aims to detect pattern of expression of PHF19 gene and EZH2 gene deletion in acute myeloid leukemia patients and detect their prognostic role on patients outcome.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Myeloid Leukemia | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cytogenetic analysis (FISH) for EZH2 gene deletion. -Real time PCR for PHF 19 gene expression. | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- acute myeloid leukemia patients - control group
- description
- acute myeloid leukemia
- interventionNames
- Diagnostic Test: Cytogenetic analysis (FISH) for EZH2 gene deletion. -Real time PCR for PHF 19 gene expression.
Primary outcomes (1)
- measure
- detection of pattern of expression of PHF19 gene and EZH2 gene deletion in newly diagnosed AML patients.
- timeFrame
- 2 years
- description
- Cytogenetic analysis (FISH) for EZH2 gene deletion. -Real time PCR for PHF 19 gene expression.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 16 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: Adult newly diagnosed Patients with acute myeloid leukemia (AML), who fullfill the WHO criteria. Exclusion Criteria: * Patients with any other type of malignant tumors. * Therapy related AML patients. * AML on top of myeloproliferative neoplasms or MDS.
References
Publications (3)
- BACKGROUNDSkoda RC, Schwaller J. Dual roles of EZH2 in acute myeloid leukemia. J Exp Med. 2019 Apr 1;216(4):725-727. doi: 10.1084/jem.20190250. Epub 2019 Mar 19. PMID 30890555
- BACKGROUNDChu MQ, Zhang TJ, Xu ZJ, Gu Y, Ma JC, Zhang W, Wen XM, Lin J, Qian J, Zhou JD. EZH2 dysregulation: Potential biomarkers predicting prognosis and guiding treatment choice in acute myeloid leukaemia. J Cell Mol Med. 2020 Jan;24(2):1640-1649. doi: 10.1111/jcmm.14855. Epub 2019 Dec 3. PMID 31794134
- BACKGROUNDRen Z, Ahn JH, Liu H, Tsai YH, Bhanu NV, Koss B, Allison DF, Ma A, Storey AJ, Wang P, Mackintosh SG, Edmondson RD, Groen RWJ, Martens AC, Garcia BA, Tackett AJ, Jin J, Cai L, Zheng D, Wang GG. PHF19 promotes multiple myeloma tumorigenicity through PRC2 activation and broad H3K27me3 domain formation. Blood. 2019 Oct 3;134(14):1176-1189. doi: 10.1182/blood.2019000578. Epub 2019 Aug 5. PMID 31383640